Segment Reporting (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Revenue: | ||||||
| Total revenue | $ 1,662 | $ 2,666 | $ 3,403 | $ 20,055 | ||
| Internal costs | ||||||
| Total research and development expense | 85,337 | 108,755 | 166,877 | 205,377 | ||
| General and administrative expenses | 23,356 | 34,450 | 41,966 | 56,745 | ||
| Intangible assets impairment loss | 41,824 | 41,824 | ||||
| Total operating expenses | 150,517 | 143,205 | 250,667 | 262,122 | ||
| Loss from operations | (148,855) | (140,539) | (247,264) | (242,067) | ||
| Total other income (expense), net | 4,877 | 191,299 | 10,233 | 193,864 | ||
| Net income (loss) before income taxes | (143,978) | 50,760 | (237,031) | (48,203) | ||
| Income tax benefit | 1,757 | 8,561 | 1,757 | 8,561 | ||
| Net income (loss) | (142,221) | $ (93,053) | 59,321 | $ (98,963) | (235,274) | (39,642) |
| License | ||||||
| Revenue: | ||||||
| Total revenue | 17,389 | |||||
| Collaboration | ||||||
| Revenue: | ||||||
| Total revenue | 1,662 | 2,666 | 3,403 | 2,666 | ||
| Single reportable segment | ||||||
| Revenue: | ||||||
| Total revenue | 1,662 | 2,666 | 3,403 | 20,055 | ||
| External costs | ||||||
| CROs, CMOs and clinical trials | 40,437 | 66,089 | 81,365 | 131,162 | ||
| Professional consulting services | 8,621 | 7,417 | 15,425 | 13,821 | ||
| Other research and development costs | 3,386 | 2,995 | 5,756 | 5,291 | ||
| Internal costs | ||||||
| Personnel-related costs | 27,212 | 26,821 | 53,277 | 44,479 | ||
| Facilities and overhead costs | 5,681 | 5,433 | 11,054 | 10,624 | ||
| Total research and development expense | 85,337 | 108,755 | 166,877 | 205,377 | ||
| General and administrative expenses | 23,356 | 34,450 | 41,966 | 56,745 | ||
| Intangible assets impairment loss | 41,824 | 41,824 | ||||
| Total operating expenses | 150,517 | 143,205 | 250,667 | 262,122 | ||
| Loss from operations | (148,855) | (140,539) | (247,264) | (242,067) | ||
| Total other income (expense), net | 4,877 | 191,299 | 10,233 | 193,864 | ||
| Net income (loss) before income taxes | (143,978) | 50,760 | (237,031) | (48,203) | ||
| Income tax benefit | 1,757 | 8,561 | 1,757 | 8,561 | ||
| Net income (loss) | (142,221) | 59,321 | (235,274) | (39,642) | ||
| Single reportable segment | License | ||||||
| Revenue: | ||||||
| Total revenue | 17,389 | |||||
| Single reportable segment | Collaboration | ||||||
| Revenue: | ||||||
| Total revenue | $ 1,662 | $ 2,666 | $ 3,403 | $ 2,666 | ||
| X | ||||||||||
- Definition Amount of research and development expenses relating to clinical research organizations, contract manufacturing organizations and clinical trials. No definition available.
|
| X | ||||||||||
- Definition n/a. No definition available.
|
| X | ||||||||||
- Definition Amount of research and development expense related to facilities and overhead. No definition available.
|
| X | ||||||||||
- Definition n/a. No definition available.
|
| X | ||||||||||
- Definition Amount of research and development expenses incurred primarily due to personnel related-costs. No definition available.
|
| X | ||||||||||
- Definition Amount of research and development expenses incurred primarily due to professional consulting services. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss for indefinite-lived intangible asset. Excludes goodwill. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|